Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines Breadcrumbs UL Home Research Publications Year of Publication 2023 Journal Cancer Research DOI 10.1158/1538-7445.SABCS22-P1-11-10